H2020HORIZON
Kks-Netzwerk Ev -Netzwerk der Koordinierungszentren fur Klinische Studien
- Country
- DEGermany
- Defence projects
- 0
- Projects, all programmes
- 10
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 7,500
- Active
- 2015 to 2022
Projects
10 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| ERA4HealthFostering a European Research Area for Health Research | HORIZON | 2022 | Third party | Not stated |
| ISIDOReIntegrated Services for Infectious Disease Outbreak Research | HORIZON | 2022 | Participant | EUR 7,500 |
| IDEA-FASTIdentifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases | H2020 | 2019 | Third party | Not stated |
| EOSC-LifeProviding an open collaborative space for digital biology in Europe | H2020 | 2019 | Third party | Not stated |
| TENSIONEfficacy and safety of thrombectomy in stroke with extended lesion and extended time window: a randomized, controlled trial | H2020 | 2018 | Third party | Not stated |
| PROOFPenumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial | H2020 | 2017 | Third party | Not stated |
| PAPA-ARTISParaplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with ‘Minimally-Invasive Segmental Artery Coil-Embolization’: A Randomized Controlled Multicentre Trial | H2020 | 2017 | Third party | Not stated |
| MACUSTARDevelop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 | H2020 | 2017 | Third party | Not stated |
| NISCIAntibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury, a multicenter European clinical proof of concept trial | H2020 | 2016 | Third party | Not stated |
| BETA3_LVHA multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease | H2020 | 2015 | Third party | Not stated |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.